Clinical Trial Update: Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) [Phase 1]

View source ↗

Summary

This clinical trial update reports that the Phase 1 study of HRS-5041 in metastatic castration-resistant prostate cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• HRS-5041

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Advanced Prostate Cancer | Phase 1 | Status: RECRUITING